Type 2 diabetes mellitus: A disease of the innate immune system? An update

Diabetic Medicine

Volumn 21, Issue 3, 2004, Pages 203-207

  Crook, M ^a,b  

^a UNIVERSITY HOSPITAL LEWISHAM   (United Kingdom)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Acute phase response; C reactive protein; Complications; Diabetes; Inflammation; Insulin resistance; Sialic acid

Indexed keywords

ACETYLSALICYLIC ACID; ACUTE PHASE PROTEIN; ALBUMIN; C REACTIVE PROTEIN; FIBRINOGEN; GROWTH HORMONE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; PRAVASTATIN; ROSIGLITAZONE; SERUM AMYLOID A; SIALIC ACID; TENIDAP; TRANSFERRIN; TUMOR NECROSIS FACTOR ALPHA;

BLOOD LEVEL; BLOOD VESSEL WALL; BODY FAT; CARDIOVASCULAR DISEASE; CORRELATION ANALYSIS; DIABETIC RETINOPATHY; ERYTHROCYTE SEDIMENTATION RATE; EXERCISE; HUMAN; IMMUNE SYSTEM; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; REVIEW; RISK FACTOR; WEIGHT REDUCTION;

EID: 1542344902     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.2003.01030.x     Document Type: Review

References (90)

1. Pickup J, Crook M. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998; 41: 1241-48.
2. Kushnet I, Rzewnicki DL. The acute phase response: general aspects. Bailliere's Clin Rheumatol 1994; 8: 513-30.
3. Schauer R. Characterisation of sialic acids. Meth Enzymol 1978; 50: 64-89.
4. Schmidt MI, Duncan BB, Sharrett AR et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities Study). Lancet 1999; 353: 1649-52.
5. Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, Tracy RP. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 2001; 50: 2384-9.
6. Lindsay RS, Krakoff J, Hanson RL, Bennett PH, Knowler WC. Gamma globulin levels predict type 2 diabetes in the Pima Indian population. Diabetes 2001; 50: 1598-1603.
7. Vozarova B, Weyer C, Lindsay RS, Pratley RE, Bogardus C, Tataranni PA. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002; 51: 455-61.
8. Ford ES. Leukocyte count, erthyrocyte sedimentation rate and diabetes incidence in a national sample of US adults. Am J Epidemiol 2002; 155: 57-64.
9. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6 and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-34.
10. Freeman D, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GDO, O'Reilly D, Packard CJ, Sattar N. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002; 51: 1596-1600.
11. Thorand B, Lowel H, Schneider A, Kolb H, Meisinger C, Frohlich M, Koenig W. C-reactive protein as a predictor for incident diabetes mellitus among middle-age men; results from the MONICA Augsburg Cohort Study, 1984-98. Arch Int Med 2003; 163: 93-9.
12. Han TS, Sattar N, Wiliams K, Gonzalez-Villalpando C, Lean ME, Haffner SM. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002; 25: 2016-21.
13. Festa A, D'Agostino R, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 (PAI-1. in the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes 2002; 51: 1131-7.
14. Srihan M, Reichelt A, Opperman ML, Duncan BB, Menge S, Crook MA, Schmidt M Total sialic acid and associated elements of the metabolic syndrome in women with and without previous gestational diabetes. Diabetes Care 2002; 251: 1331-5.
15. Pickup JC, Mattock MB, Chusney CD, Burt D. NIDDM as a disease of the innate immune system. association of acute-phase reactants and IL-6 with metabolic syndrome X. Diabetologia 1997; 40: 1286-92.
16. Crook M, Bharba S, Lumb P. The relationship between serum sialic acid and IL-6 in type 2 diabetes mellitus. Med Biochem 1998; 3: 60-3.
17. Grau AJ, Buggle F, Becher H, Werle E, Hacke W. The association of leukocyte count, fibrinogen and C-reactive protein with vascular risk factors and ischaemic vascular diseases. Thromb Res 1996; 82: 245-55.
18. Wu T, Dorn JP, Donahue RP, Sempos CT, Trevisan M. Associations of serum C-reactive protein with fasting insulin, glucose, and glycosylated hemoglobin: the Third National Health Nutrition Examination Survey, 1988-94. Am J Epidemiol 2002; 155: 65-71.
19. Festa A, D'Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-47.
20. Frohlich M, Imhof A, Berg G. Association between C-reactive protein and features of the metabolic syndrome: a population based study. Diabetes Care 2000; 23: 1835-39.
21. Ford ES. Body mass index, diabetes and C-reactive protein among US adults. Diabetes Care 1999; 22: 1971-77.
22. Wakabayashi I, Sakamoto K, Yoshimoto S, Masiu H. Relation of serum sialic acid to lipid concentrations. Br Med J 1992; 305: 562-563.
23. Haq S, Haq M, Tutt P, Crook M. Serum sialic acid and acute phase proteins in hypertriglyceridaemic patients showing the Frederickson's type IIB phenotype. Clin Sci 1993; 85: 219-222.
24. Crook M, Haq S, Haq M, Tutt P. The relationship serum total sialic acid with serum acute phase proteins and lipoprotein (a) in patients with severe hypertriglyceridaemia. Eur J Clin Invest 1994; 24: 179-181.
25. Lindberg G, Rastam L, Gullberg B, Lundblad A, Nilsson-Ehle P, Hanson BS. Serum concentrations of total sialic acid and glycoproteins in relation to coronary heart disease risk markers. Atherosclerosis 1993; 103: 123-129.
26. Feingold KR, Grunfeld C. Role of cytokines in inducing hyperlipidaemia. Diabetes 1992; 41S: 97-101.
27. Hotamisligil GS, Spiegelman BM. Tumour necrosis factor-alpha: a key component of the obesity-diabetes link. Diabetes 1994; 43: 1271-78.
28. Ponnio M, Alho H, Nikkari ST, Olsson U, Rydberg U, Sillanaukee P. Serum sialic acid in a random sample of the general population. Clin Chem 1999; 45: 1842-49.
29. Crook M, Andrews V, Lumb P, Swaminathan R. Serum sialic acid, a reputed cardiovascular risk factor, and its relationship to serum lipids, fasting plasma insulin and glucose and blood pressure in healthy individuals. Clin Sci 1998; 95: 53-57.
30. Haverkate F, Thompson SG, Pyke SDM, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997; 349: 462-6.
31. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Medical 1997; 336: 973-9.
32. Lindberg G, Eklund G, Gullberg B, Rastam L. Serum sialic acid concentration and cardiovascular mortality. Br Med J 1991; 302: 143-46.
33. Pickup JC, Mattock MB, Crook MA, Chusney GD, Burt D, Fitzgerald AP. Serum sialic acid concentration and coronary heart disease in NIDDM. Diabetes Care 1995; 18: 1100-1103.
34. Lagrand WK, Visser CA, Hermans WT, Niessen HW, Verheught FW, Wolbink GJ, Hack CE. C-reative protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation 1999; 100: 96-102.
35. Blake G, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res 2001; 89: 763-71.
36. Johnsson A, Wales JK. Blood glycoprotein levels in diabetes mellitus. Diabetologia 1976; 12: 245-250.
37. Ganrot PO, Gydelli K, Ekelund H. Serum concentration of alpha-2-macroglobulin, haptoglobin and alpha-1-antitrypsin in diabetes mellitus. Acta Endocr 1967; 55: 537-544.
38. McMillan DE. Increased levels of acute phase serum proteins in diabetes. Metabolism 1989; 38: 1042-1046.
39. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T. Strong association between malnutrition, inflammation and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899-911.
40. Hak AE, Stehouwer CD, Bots ML, Polderman KH, Schalkwijk CG, Westendorp IC, Hofman A, Witteman JC. Associations of C-reactive protein with measures of obesity, insulin resistance and sub-clinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol 1999; 19: 1986-91.
41. Folsom AR, Pankow JS, Tracy RP, Arnett DK, Hong Y, Djousse L, Eckfeldt JH, the investigators of the NHBLI Family Heart Study. Association of C-reactive protein with markers of prevalent atherosclerotic disease. Am J Cardiol 2001; 88: 112-7.
42. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731-33.
43. Tracy RP, Memaitre RN, Psaty BM, Ives DG, Evans RN, Cushman M, Meilahn M, Kuller LH. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly; results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997; 17: 1121-27.
44. Tomino Y, Inoue W, Yagame M. Measurement of sialic acid and acute phase reactant proteins in sera of patients with diabetic retinopathy. J Diab Compl 1988; 2: 175-178.
45. Crook M, Tutt P, Pickup JC. Serum sialic acid in non-insulin dependent diabetes mellitus and its relationship to blood pressure and retinopathy. Diabetes Care 1993; 16: 57-60.
46. Crook M, Simpson H, Tutt P, Pickup J. Serum total sialic acid and acute phase proteins in type 1 diabetes mellitus. Clin Chim Acta 1993; 219: 131-138.
47. Ozben T, Nacitarhan S, Tuncer N. Plasma and urine sialic acid in NIDDM. Ann Clin Biochem 1995; 32: 303-308.
48. Chen J, Gall MA, Yokoyama H, Jensen JS, Deckert M, Parving HH. Raised serum sialic acid concentration in NIDDM patients with and without diabetic nephropathy. Diabetes Care 1996; 19: 130-4.
49. Suzuki K, Ishida H, Sugimoto C, Taguchi Y, Matsuda H, Nosaka K, Someya Y, Kadowaki S, Seino Y. The urinary concentration of sialic acid is increased in NIDDM patients with microangiopathy: a possible marker for diabetic microangiopathy. Diabetic Med 1995; 12: 1092-1096.
50. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction and chronic low-grade inflammation in type 2 diabetes; progressive, interrelated and independently associated with risk of death. Diabetes 2002; 51: 1157-65.
51. Festa A, D'Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study Kidney Int 2000; 58: 1703-10.
52. Yokoyama H, Jensen JS, Myrup B, Mathiesen ER, Ronn B, Deckert T. Raised serum sialic acid concentration precedes onset of microalbuminuria in IDDM. Diabetes Care 1996; 19: 435-40.
53. Pedersen LM, Nordin H, Svensson B, Bliddal H. Microalbuminuria in patients with rheumatoid arthritis. Ann Rheum Dis 1995; 54: 189-92.
54. Mahmud N, McDonald GS, Kelleher D, Weir DG. Microalbuminuria correlates with intestinal histopathological grading in patients with inflammatory bowel disease. Gut 1996; 38: 99-103.
55. Temelkova-Kurktschiev T, Siegert G, Bergmann S, Henkel E, Koehle C, Jaross W, Hanefeld M. Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. Metabolism 2002; 51: 743-9.
56. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance and endothelial dysfunction: a potential role for cytokines originating from adipose tissue. Arterioscler Thromb Vasc Biol 1999; 19: 972-78.
57. Mohamed-Ali V, Goodrick S, Rawesh A, Coppack SW, Yudkin JS. Subcutaneous adipose tissue releases IL-6 but not tumour necrosis factor in vivo. J Clin Endocrinol Metab 1997; 82: 4196-200.
58. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release IL-6 depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998; 83: 847-50.
59. Festa A, D'Agostino R, Williams K, Karter AJ, Mayer-Davis EJ, Tracy RP, Haffner SM. The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes Relat Metab Disord 2001; 25: 1407-15.
60. Pannacciulli N, Cantatore FP, Minenna A, Bellacicco M, Giorgino R, De Pergola G. C-reactive protein is independently associated with total body fat, central fat and insulin resistance in adult women. Int J Obes Relat Metab Discord 2001; 25: 1416-20.
61. Campos SP, Baumann H. Insulin is a prominent modulator of the cytokine stimulated expression of acute phase plasma protein genes. Mol Cell Biol 1992; 12: 1789-1797.
62. Thompson D, Harrison SP, Evans SW, Whicher JT. Insulin modulation of acute-phase protein production in a human hepatoma-line. Cytokine 1991; 3: 619-626.
63. Feingold KR, Grunfeld C. Tumor necrosis factor-alpha stimulates hepatic lipogenesis in the rat in vivo. J Clin Invest 1987; 80: 184-90.
64. Coppack SW. Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc 2001; 60: 349-56.
65. Liu S, Manson JE, Buring JE, Stamfer MJ, Willett WC, Ridker PM. Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle aged women. Am J Clin Nutr 2002; 75: 492-8.
66. Zahedi R, Summers L, Lumb P, Crook M. Effect of an oral fat load upon serum sialic acid in normal individuals. Eur J Int Med 2002; 12: 510-514.
67. Crook M, Andrews V, Lumb P, Swaminathan R. Serum sialic acid is elevated in South Asian males compared to Caucasian males. Ann Clin Biochem 1998; 35: 242-44.
68. Chambers JC, Eda S, Bassett P, Karim Y, Thompson SG, Gallimore JR, Pepys MB, Kooner JS. CRP, insulin resistance, central obesity and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation 2002; 104: 145-50.
69. Grossi SG, Genco RJ. Peridontal disease and diabetes mellitus: a two way relationship. Ann Peridontol 1998; 3: 51-61.
70. Patel P, Mendall MA, Carrington D, Strachan DP, Leatham E, Molinneaux N, Levy J, Blakeston C, Seymour CA, Camm AJ. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ 1995; 311: 711-4.
71. Ikonomidis I, Andreottit F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999; 100: 793-8.
72. Feldman M, Jialal I, Devaraj S, Cryer B. Effects of low-dose aspirin on CRP and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive CRP assay. J Am Coll Cardiol 2001; 37: 2036-41.
73. Feng D, Tracy RP, Lipinska I, Murillo J, McKenna C, Tofler GH. Effect of short-term aspirin use on CRP. J Thromb Thrombolysis 2000; 9: 37-41.
74. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, Shepherd J, Gaw A. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland and Coronary Prevention Study. Circulation 2001; 103: 346-7.
75. Albert MA, Danielson E, Rifai N, Ridker PM, PRINCE Investigators. Effect of statin therapy on CRP levels: the Pravastatin inflammation/CRP evaluation (PRINCE): a randomised trial and cohort study. JAMA 2001; 286: 64-70.
76. Palinski W. New evidence for beneficial effects of statins unrelated to lipid lowering. Arterio Thromb Vasc Biol 2001; 21: 3-5.
77. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on non-traditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-84.
78. Marx N. PPARgamma and vascular inflammation: adding another piece to the puzzle. Circ Res 2002; 91: 373-4.
79. Sesmilo G, Biller BMK, Llevadot J. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. Ann Intern Med 2000; 133: 111-122.
80. Christ E, Cummings M, Crook M, Lumb P, Sonksen P. Growth hormone replacement therapy reduces sialic acid in adults with growth hormone deficiency. Clin Endo 1999; 51: 173-9.
81. Chernoff AE, Granowitz EV, Shapiro L. A randomised, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol 1995; 154: 5492-5499.
82. McNiff PA, Laliberte RE, Svensson L, Pazoles CJ, Gabel CA. Inhibition of cytokine activation processes in vitro by tendicap a novel anti-inflammatory agent. Cytokine 1995; 7: 196-208.
83. Ventre J, Doebber T, Wu M. Targeted disruption of the tumour necrosis factor-alpha gene. Metabolic consequences in obese and nonobese mice. Diabetes 1997; 46: 1526-31.
84. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity induced insulin resistance in mice lacking TNF-alpha function. Nature 1997; 389: 610-14.
85. Ford ES. Does exercise reduce inflammation? Physical activity and CRP among US adults. Epidemiology 2002; 13: 561-8.
86. Wigmore SJ, Fearon KC, Ross JA. Modulation of human heparocyte acute phase protein production in vitro by n-3 and n-6 polyunsaturated fatty acid. Ann Surg 1997; 225: 103-11.
87. Grimble RF. Nutritional modulation of cytokine biology. Nutrition 1998; 14: 634-40.
88. Madsen T, Skou HA, Hansen VE, Fog L, Christensen JH, Toft E, Schmidt EB. C-reactive protein, dietary n-3 fatty acids and the extent of coronary artery disease. Am Cardiol 2001; 88: 1139-42.
89. Ziccardi P, Nappo F, Giugliano G, Esposito K, Marfella R, Cioffi M, D'Andrea F, Molinari AM, Giugliano D. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002; 105: 804-9.
90. Tchernof A, Nolan A, Sites CK, Ades PA, Poehlman ET. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation 2002; 105: 564-9.